CHOK1BN細胞株は、ECACCから提供され、CD培地での懸濁培養に特化して適応されたもので、抗体関連研究において有用です。この細胞株は、元のCHO細胞株から完全にトレース可能であり、商業利用のためにサブライセンスすることができます。中国とアメリカの両方の登録要件に準拠しており、抗体の開発と製造において信頼性がありアクセスしやすい選択肢となっています。さらに、ライセンスは永久的で取り消し不可能です。
BiointronのCHOK1BN細胞株はECACCからライセンスされています。(契約番号 BYC-SHSWZP211027)
提供内容 | 詳細 |
---|---|
ホスト細胞株 |
|
ドキュメンテーション |
|
プロトコル |
|
A CHOK1BN cell line sublicense is a legal agreement that allows a third party (the sublicensee) to use the CHOK1BN cell line, which is owned by another entity (the licensor), for purposes such as research, development, or commercial reasons.
Sublicensing allows the original licensor to expand the reach and potential applications of their cell line technology while providing the sublicensee with access to valuable research tools or resources. It is a common practice in the biotechnology and pharmaceutical industries, where cell lines are frequently used as essential tools in various scientific endeavors and therapeutic development.
There are numerous applications for the use of the CHOK1BN cell line sublicense, including drug discovery and development, biomanufacturing, diagnostic development, genetic engineering, viral vector production, and in vitro disease modeling.
Chinese hamster ovary (CHO) cell lines are derived from the ovary of adult, female Chinese hamsters. CHO cells were first established in 1957 by T. Puck, and were subsequently multiplied and optimized in vitro, allowing it to be cultured indefinitely. The CHO-K1 cell line was derived as a subclone from that parental CHO cell line. They are typically the preferred host expression system for recombinant antibodies due to their advantages in producing complex therapeutics and manufacturing adaptability.1